The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
Subscribe To Our Newsletter & Stay Updated